| Item 7.01. | Regulation FD Disclosure. |
On August 1, 2022, GreenLight Biosciences Holdings, PBC (the “Company”), issued a press release announcing that the first commercial-scale engineering run for the production of the Company’s mRNA vaccine candidate has been completed through the Company’s relationship with Samsung Biologics Co., Ltd. A copy of the press release is set forth as Exhibit 99.1 and is incorporated by reference herein.
The information contained in this Item 7.01 of this Current Report on Form 8-K (this “report) and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Cautionary Note Regarding Forward Looking Statements
The press release attached as Exhibit 99.1 to this report contains, and our officers, directors and employees may make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the future operations, scientific developments or financial results of the Company, the Company’s relationship with Samsung Biologics and the manufacturing and scale-up of its product candidates. These forward-looking statements generally are identified by the words “aim to”, “believe,” “project,” “target”, “potential”, “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in the press release, including the evolution of the COVID-19 pandemic, the ability to develop COVID-19 vaccines that are more broadly protective against new variants and with longer-lasting effects, the ability to begin clinical trials for the Company’s COVID-19 booster vaccine candidate in 2022, the ability to rapidly develop and deploy vaccines on a commercial scale or at all, unanticipated challenges in advancing large-scale commercial production, the ability to scale up and the compatibility of the Company’s process to Samsung Biologics’ Songdo facility, the ability to replicate the production scale in future engineering runs, the acceptance of RNA-based technologies by regulators and the public, our ability to raise and productively deploy capital and the rate at which we can successfully bring products to market. Readers are cautioned not to put undue reliance on forward-looking statements and are encouraged to read the additional risks and uncertainties discussed in our periodic filings with the Securities and Exchange Commission under the heading “Risk Factors.” The Company assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For additional information on the Company’s and potential risks associated with investing in the Company’s securities, please see our public filings at https://www.sec.gov/edgar/browse/?CIK=1822691&owner=exclude.
